Search

Your search keyword '"Fulvio, Zaccagna"' showing total 2 results
Start Over Author "Fulvio, Zaccagna" Publisher public library of science (plos)
2 results on '"Fulvio, Zaccagna"'

1. Multiparametric MRI for assessment of early response to neoadjuvant sunitinib in renal cell carcinoma

Author

Stephan Ursprung, Andrew N. Priest, Fulvio Zaccagna, Wendi Qian, Andrea Machin, Grant D. Stewart, Anne Y. Warren, Timothy Eisen, Sarah J. Welsh, Ferdia A. Gallagher, and Tristan Barrett

Subjects
Medicine, Science
Abstract

Purpose To detect early response to sunitinib treatment in metastatic clear cell renal cancer (mRCC) using multiparametric MRI. Method Participants with mRCC undergoing pre-surgical sunitinib therapy in the prospective NeoSun clinical trial (EudraCtNo: 2005-004502-82) were imaged before starting treatment, and after 12 days of sunitinib therapy using morphological MRI sequences, advanced diffusion-weighted imaging, measurements of R2* (related to hypoxia) and dynamic contrast-enhanced imaging. Following nephrectomy, participants continued treatment and were followed-up with contrast-enhanced CT. Changes in imaging parameters before and after sunitinib were assessed with the non-parametric Wilcoxon signed-rank test and the log-rank test was used to assess effects on survival. Results 12 participants fulfilled the inclusion criteria. After 12 days, the solid and necrotic tumor volumes decreased by 28% and 17%, respectively (p = 0.04). However, tumor-volume reduction did not correlate with progression-free or overall survival (PFS/OS). Sunitinib therapy resulted in a reduction in median solid tumor diffusivity D from 1298x10-6 to 1200x10-6mm2/s (p = 0.03); a larger decrease was associated with a better RECIST response (p = 0.02) and longer PFS (p = 0.03) on the log-rank test. An increase in R2* from 19 to 28s-1 (p = 0.001) was observed, paralleled by a decrease in Ktrans from 0.415 to 0.305min-1 (p = 0.01) and a decrease in perfusion fraction from 0.34 to 0.19 (pConclusions Physiological imaging confirmed efficacy of the anti-angiogenic agent 12 days after initiating therapy and demonstrated response to treatment. The change in diffusivity shortly after starting pre-surgical sunitinib correlated to PFS in mRCC undergoing nephrectomy, however, no parameter predicted OS. Trial registration EudraCtNo: 2005-004502-82.

Published
2021

2. Multiparametric MRI for assessment of early response to neoadjuvant sunitinib in renal cell carcinoma

Author

Ferdia A. Gallagher, Wendi Qian, Fulvio Zaccagna, Stephan Ursprung, Grant D. Stewart, Anne Y. Warren, Sarah J. Welsh, Tristan Barrett, Timothy Eisen, Andrew N. Priest, Andrea Machin, Ursprung, Stephan [0000-0003-2476-178X], Priest, Andrew N. [0000-0002-9771-4290], Warren, Anne Y. [0000-0002-1170-7867], Apollo - University of Cambridge Repository, Priest, Andrew N [0000-0002-9771-4290], Stewart, Grant [0000-0003-3188-9140], Warren, Anne [0000-0002-1170-7867], Eisen, Tim [0000-0001-9663-4873], Welsh, Sarah [0000-0001-5690-2677], Gallagher, Ferdia [0000-0003-4784-5230], Barrett, Tristan [0000-0002-1180-1474], Ursprung S., Priest A.N., Zaccagna F., Qian W., Machin A., Stewart G.D., Warren A.Y., Eisen T., Welsh S.J., Gallagher F.A., Barrett T., and Warren, Anne Y [0000-0002-1170-7867]

Subjects
Male, medicine.medical_treatment, Cancer Treatment, urologic and male genital diseases, Nephrectomy, Metastasis, Diagnostic Radiology, Renal cell carcinoma, Basic Cancer Research, Medicine and Health Sciences, Sunitinib, ComputingMilieux_MISCELLANEOUS, Brain Mapping, Multidisciplinary, medicine.diagnostic_test, Radiology and Imaging, Middle Aged, Magnetic Resonance Imaging, Kidney Neoplasms, Neoadjuvant Therapy, Treatment Outcome, Oncology, Nephrology, Renal Cancer, Medicine, Female, Perfusion, medicine.drug, MRI, Research Article, medicine.medical_specialty, Imaging Techniques, Brain Morphometry, Science, Urology, Surgical and Invasive Medical Procedures, Neuroimaging, Antineoplastic Agents, Research and Analysis Methods, Urinary System Procedures, Diagnostic Medicine, medicine, Humans, Multiparametric Magnetic Resonance Imaging, Carcinoma, Renal Cell, Aged, Surgical Excision, business.industry, Diffusion Weighted Imaging, Carcinoma, Renal Cell Carcinoma, Cancer, Cancers and Neoplasms, Biology and Life Sciences, Magnetic resonance imaging, medicine.disease, Clinical trial, Genitourinary Tract Tumors, business, Neuroscience
Abstract

Funder: NIHR Cambridge Biomedical Research Centre, Funder: Addenbrooke’s Charitable Trust, Funder: National Institute for Health Research (NIHR), Funder: Mark Foundation For Cancer Research, Funder: Cambridge Commonwealth, European and International Trust, Funder: Cancer Research UK, Funder: Cambridge Clinical Trials Unit, Funder: Cancer Research UK Cambridge Centre, Funder: Engineering and Physical Sciences Research Council Cancer Imaging Centre in Cambridge and Manchester, Funder: Cambridge Experimental Cancer Medicine Centre, PURPOSE: To detect early response to sunitinib treatment in metastatic clear cell renal cancer (mRCC) using multiparametric MRI. METHOD: Participants with mRCC undergoing pre-surgical sunitinib therapy in the prospective NeoSun clinical trial (EudraCtNo: 2005-004502-82) were imaged before starting treatment, and after 12 days of sunitinib therapy using morphological MRI sequences, advanced diffusion-weighted imaging, measurements of R2* (related to hypoxia) and dynamic contrast-enhanced imaging. Following nephrectomy, participants continued treatment and were followed-up with contrast-enhanced CT. Changes in imaging parameters before and after sunitinib were assessed with the non-parametric Wilcoxon signed-rank test and the log-rank test was used to assess effects on survival. RESULTS: 12 participants fulfilled the inclusion criteria. After 12 days, the solid and necrotic tumor volumes decreased by 28% and 17%, respectively (p = 0.04). However, tumor-volume reduction did not correlate with progression-free or overall survival (PFS/OS). Sunitinib therapy resulted in a reduction in median solid tumor diffusivity D from 1298x10-6 to 1200x10-6mm2/s (p = 0.03); a larger decrease was associated with a better RECIST response (p = 0.02) and longer PFS (p = 0.03) on the log-rank test. An increase in R2* from 19 to 28s-1 (p = 0.001) was observed, paralleled by a decrease in Ktrans from 0.415 to 0.305min-1 (p = 0.01) and a decrease in perfusion fraction from 0.34 to 0.19 (p

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results